|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Did the Study Attempt to Enroll** **All (or a Random Sample of) Patients Meeting Inclusion Criteria, or a Random Sample?** | **Were the Groups Comparable at Baseline on** **Key Prognostic Factors?** | **Did the Study Maintain Comparable Groups Through** **the Study Period?** | **Did the Study Use Accurate Methods for Ascertaining Exposures and Potential Confounders?** | **Were Outcome Assessors and/ or Data Analysts Blinded to the Exposure Being Studied?** | **Did the Article Report Attrition?** | **Did the Study Perform Appropriate Statistical Analyses on Potential Confounders?** | **Is There Important Differential or Overall High Loss to Followup?** | **Were Outcomes Prespecified and Defined, and Ascertained Using Accurate Methods?** | **Quality Rating** |
| Razvi 201249 | Yes | No; thyrotropin level was significantly different between treated and nontreated groups | Unclear | Did not adjust for use of aspirin, lipid- lowering therapy, or cardiovascular medications | Not applicable | Not applicable | Did not adjust for use of aspirin, lipid-lowering therapy, or cardiovascular medications | Not applicable | Yes | Fair |